The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis

被引：0
作者：
Zhao, Zi-Jing [1 ,2 ,3 ]
Lian, Hong-Yun [1 ,2 ,3 ,4 ]
Li, Wei-Jing [1 ,2 ,3 ]
Zhang, Qing [1 ,2 ,3 ]
Ma, Hong-Hao [2 ,3 ,4 ]
Wang, Dong [2 ,3 ,4 ]
Zhao, Yun-Ze [2 ,3 ,4 ]
Zhu, Ting [1 ,2 ,3 ]
Li, Hua-Lin [1 ,2 ,3 ]
Huang, Xiao-Tong [1 ,2 ,3 ]
Wang, Tian-You [2 ,3 ,4 ]
Zhang, Rui [2 ,3 ,4 ]
Cui, Lei [1 ,2 ,3 ]
Li, Zhi-Gang [1 ,2 ,3 ]
机构：
[1] Capital Med Univ, Beijing Childrens Hosp, Beijing Pediat Res Inst, Natl Ctr Childrens Hlth,Hematol Dis Lab, Beijing, Peoples R China
[2] Capital Med Univ, Natl Key Discipline Pediat, Beijing, Peoples R China
[3] Minist Educ, Key Lab Major Dis Children, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Hematol ,Hematol Ctr, Beijing, Peoples R China
来源：
JORNAL DE PEDIATRIA | 2025年 / 101卷 / 02期
基金：
中国国家自然科学基金; 北京市自然科学基金;
关键词：
Langerhans cell histiocytosis; sCD25; Prognosis; Relapse; CYTOKINES; IL-2; LCH;
D O I：
10.1016/j.jped.2024.08.005
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Objective: Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm with inflammatory characteristics. This study aims to investigate the correlation between sCD25 levels and clinical characteristics, as well as prognosis, in pediatric LCH. Methods: Serum sCD25 levels were measured in 370 LCH patients under 18 years old using ELISA assays. The patients were divided into two cohorts based on different treatment regimens. We further assessed the predictive value for the prognosis impact of sCD25 in a test cohort, which was validated in the independent validation cohort. Results: The median serum sCD25 level at diagnosis was 3908 pg/ml (range: 231-44 000pg/ml). sCD25 level was significantly higher in multi-system and risk organ positive (MS RO+) LCH patients compared to single-system(SS) LCH patients (p < 0.001). Patients with elevated sCD25 were more likely to have involvement of risk organs, skin, lung, lymph nodes, or pituitary (all p < 0.05). sCD25 level could predict LCH progression and relapse, with an area under the ROC curve of 60.6 %. The optimal cutoff value was determined at 2921 pg/ml. Patients in the highsCD25 group had significantly worse progression-free survival compared to those in the lowsCD25 group (p < 0.05). Conclusion: Elevated serum sCD25 level at initial diagnosis was associated with high-risk clinical features and worse prognosis. sCD25 level can predict the progression/recurrence of LCH following first-line chemotherapy.
引用
收藏
页码：194 / 201
页数：8
相关论文
共 30 条
  • [1] Rodriguez-Galindo C., Allen C.E., Langerhans cell histiocytosis, Blood, 135, pp. 1319-1331, (2020)
  • [2] Gulati N., Allen C.E., Langerhans cell histiocytosis: version 2021, Hematol Oncol, 39, pp. S15-S23, (2021)
  • [3] Durham B.H., Lopez Rodrigo E., Picarsic J., Abramson D., Rotemberg V., de Munck S., Et al., Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms, Nat Med, 25, pp. 1839-1842, (2019)
  • [4] Badalian-Very G., Vergilio J.A., Degar B.A., MacConaill L.E., Brandner B., Calicchio M.L., Et al., Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood, 116, pp. 1919-1923, (2010)
  • [5] Allen C.E., Longo D.L., Merad M., McClain K.L., Langerhans-cell histiocytosis, N Engl J Med, 379, pp. 856-868, (2018)
  • [6] Haroche J., Cohen-Aubart F., Rollins B.J., Donadieu J., Charlotte F., Idbaih A., Et al., Histiocytoses: emerging neoplasia behind inflammation, Lancet Oncol, 18, pp. e113-e125, (2017)
  • [7] Allen C.E., Ladisch S., McClain K.L., How I treat Langerhans cell histiocytosis, Blood, 126, pp. 26-35, (2015)
  • [8] Tazi A., Moreau J., Bergeron A., Dominique S., Hance A.J., Soler P., Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment, J Immunol, 163, pp. 3511-3515, (1999)
  • [9] Cai F., Peng Z., Xu H., Gao H., Liao C., Xu X., Et al., Immune microenvironment associated with the severity of Langerhans cell histiocytosis in children, Cytokine, 171, (2023)
  • [10] Morimoto A., Oh Y., Nakamura S., Shioda Y., Hayase T., Imamura T., Et al., Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis, Cytokine, 97, pp. 73-79, (2017)
123